首页> 外文期刊>Journal of neuroinflammation >Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia
【24h】

Mechanisms of action of naturally occurring antibodies against β-amyloid on microglia

机译:天然抗β-淀粉样蛋白抗体对小胶质细胞的作用机制

获取原文
获取外文期刊封面目录资料

摘要

Background Naturally occurring autoantibodies against amyloid-β (nAbs-Aβ) have been shown to exert beneficial effects on transgenic Alzheimer’s disease (AD) animals in vivo and on primary neurons in vitro. Not much is known about their effect on microglial cells. Our aim was to investigate the effect of nAbs-Aβ on amyloid-β (Aβ)-treated microglial cells in vitro with respect to cell viability, stress pathways, cytokine production and phagocytotic abilities and whether these effects can be conveyed to neurons. Methods Primary microglial cells isolated from Swiss Webster mouse mesencephalons on embryonic day 13.5 were pretreated with nAbs-Aβ and then treated with Aβ oligomers. After 3 hours, phagocytosis as well as western blot analysis were evaluated to measure the amount of phagocytized Aβ. Cell viability was analyzed using an MTT assay 24 hours after treatment. Pro-inflammatory cytokines in the supernatants were analyzed with ELISAs and then we treated primary neuronal cells with these conditioned microglia supernatants. Twenty-four hours later we did a MTT assay of the treated neurons. We further investigated the effect of a single nAbs-Aβ administration on Tg2576 mice in vivo. Results Upon co-administration of Aβ and nAbs-Aβ no change in microglia viability was observed. However, there was an increase in phosphorylated p38 protein level, an increase in the pro-inflammatory cytokines TNF-α and IL-6 and an increase in Aβ uptake by microglial cells. Treatment of primary neurons with conditioned microglia medium led to a 10% improvement in cell viability when nAbs-Aβ were co-administered compared to Aβ-treated cells alone. We were unable to detect changes in cytokine production in brain lysates of Tg2576 mice. Conclusions We provide evidence on the mechanism of action of nAbs-Aβ on microglia in vitro. Interestingly, our in vivo data indicate that nAbs-Aβ administration should be considered as a therapeutic strategy in AD, since there is no inflammatory reaction.
机译:背景技术天然存在的针对淀粉样β的自身抗体(nAbs-Aβ)已显示出对体内转基因阿尔茨海默氏病(AD)动物和体外原代神经元具有有益作用。关于它们对小胶质细胞的作用还知之甚少。我们的目的是在细胞活力,应激途径,细胞因子产生和吞噬能力方面研究nAbs-Aβ对淀粉样β(Aβ)处理的小胶质细胞的体外作用,以及这些作用是否可以传递给神经元。方法在胚胎第13.5天从Swiss Webster小鼠中脑分离的原代小胶质细胞用nAbs-Aβ预处理,然后用Aβ寡聚体处理。 3小时后,评估吞噬作用和蛋白质印迹分析以测量吞噬的Aβ的量。处理后24小时,使用MTT测定法分析细胞活力。用ELISA分析上清液中的促炎细胞因子,然后用这些条件化的小胶质细胞上清液处理原代神经元细胞。二十四小时后,我们对所治疗的神经元进行了MTT分析。我们进一步研究了单次nAbs-Aβ给药对Tg2576小鼠体内的影响。结果在同时施用Aβ和nAbs-Aβ时,未观察到小胶质细胞活力的变化。然而,磷酸化的p38蛋白水平增加,促炎性细胞因子TNF-α和IL-6增加,并且小胶质细胞摄取Aβ增加。与单独使用Aβ处理的细胞相比,当同时施用nAbs-Aβ时,用条件性小胶质细胞培养基处理原代神经元可使细胞活力提高10%。我们无法检测到Tg2576小鼠脑裂解物中细胞因子产生的变化。结论我们提供了有关nAbs-Aβ对小胶质细胞体外作用机理的证据。有趣的是,我们的体内数据表明,nAbs-Aβ给药应被认为是AD的治疗策略,因为它没有炎症反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号